Page last updated: 2024-11-12

5-Bromopyridin-3-yl furan-2-carboxylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID16203681
CHEMBL ID222234
CHEBI ID149861

Synonyms (6)

Synonym
CHEMBL222234 ,
bdbm50208940
5-bromopyridin-3-yl furan-2-carboxylate
5-bromo-pyridin-3-yl furan-2-carboxylate
CHEBI:149861
(5-bromopyridin-3-yl) furan-2-carboxylate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.05000.03002.29719.5100AID1804126; AID281492
Replicase polyprotein 1abHuman coronavirus 229EIC50 (µMol)0.05000.03002.14419.5100AID1804126
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)0.05000.00402.92669.9600AID1804126; AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)0.05000.00022.45859.9600AID1805801
Genome polyproteinrhinovirus A16IC50 (µMol)0.08000.08000.08000.0800AID375502
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID281491Inhibition of SARS coronavirus His-3C-like protease at 100 uM2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.
AID384259Activity of hepatitis A virus 3C proteinase assessed as compound hydrolysis by HPLC2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID375502Inhibition of HRV-16 protease 3C expressed in Escherichia coli BL21(DE3) by FRET assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.
AID384255Inhibition of hepatitis A virus 3C proteinase by microplate assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID384260Activity of SARS coronavirus 3CL proteinase assessed as compound hydrolysis by HPLC2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID281492Inhibition of SARS coronavirus 3C-like protease2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.
AID281493Inhibition of SARS coronavirus 3C-like protease at 1 uM2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters.
AID384257Inhibition of hepatitis A virus 3C proteinase at 1 uM by microplate assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID375500Inhibition of HRV-16 protease 3C expressed in Escherichia coli BL21(DE3) at 1 uM by FRET assay2009Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13
Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.
AID384256Inhibition of hepatitis A virus 3C proteinase at 10 uM by microplate assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID384262Ratio of Kcat to Km of SARS coronavirus 3CL proteinase2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID384254Inhibition of SARS coronavirus 3CL proteinase2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID384261Ratio of Kcat to Km of hepatitis A virus 3C proteinase2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID384258Inhibition of hepatitis A virus 3C proteinase at 0.25 uM by microplate assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID384263Stability in buffer assessed as half life of hydrolysis2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
AID1804126No assay is provided from Article 10.1021/acs.jmedchem.5b01461: \\An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.\\2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]